Treatment of haemophilia A in Tunisia: Efficacy and inhibitor study

Hamostaseologie

Volumn 23, Issue 3, 2003, Pages 144-148

  Houissa, Botoul ^a   Mliki, M L ^a   Abdelkafi, S ^a   Bouslama, M ^a   Zaier M ^a   Mahjoub, T ^a   Kortas, M ^a   Ghachem, L ^a   Yacoub, S ^a  

^a FARHAT HACHED HOSPITAL   (Tunisia)

Author keywords

Factor VIII; Haemophilia A; Inhibitors; Recovery

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; FRESH FROZEN PLASMA;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CRYOPRECIPITATE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; MALE; PLASMAPHERESIS; SIDE EFFECT; TREATMENT OUTCOME; TUNISIA;

EID: 0041932367     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1619585     Document Type: Article

References (27)

1. Tuddenham EGD, Schwaab R, Seehafer J et al. Haemophilia A: database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene. Nucleic Acids Res 1994;22:3511-33.
2. Oldenburg J, Brackmann HH, Hanfland P et al. Molecular genetics in haemophilia A. Vox Sang 2000;78(suppl 2):33-8.
3. Bell B, Canty D, Audet M. Hemophilia: an updated review. Pediatr Rev 1995;16:290-8.
4. Lusher JM, Warrier I. Hemophilia A. Hematol Oncol Clin North Am 1992;6:1021-33.
5. Bouma BN, Starkenborg AE. Dilution of hemophilia plasma used as a reagent in the determination of anti-hemophilia factor A (Factor VIII). Haemost 1974;3:94-7.
6. Allain JP, Verroust F, Soulier JP. In vitro and in vivo characterization of factor VIII preparations. Vox Sang 1980;38:68-80.
7. Kasper C, Aledort L, Counts R et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975;34:869-72.
8. Aledort L. Inhibitors in hemophilia patients: Current status and management. Am J Hematol 1994;47:208-17.
9. Verbruggen B, Novakova I, Wessels H et al. The Nijmegen modification of the Bethesda assay for factor VIII: C inhibitors: improved specificity and reliability. Thromb Haemost 1995;73:247-51.
10. Messori A, Longo G, Matucci M et al. Clinical pharmacokinetics of factor VIII in patients with classic haemophilia. Clin Pharmacokinet 1987;13:365-80.
11. Mc Millan CW, Sandor S, Shapiro SS et al. Hemophilia Study Group. The natural history of factor VIII: C inhibitors in patients with hemophilia A: a national cooperative Study II. Observations on the initial development of factor VIII: C inhibitors. Blood 1988;71: 344-8.
12. Mc Verry BA, Machin SJ. Incidence of alloimmunization and allergic reactions to cryoprecipitate in haemophilia. Vox Sang 1979;36: 77-80.
13. Aznar JA, Montoro JM, Cid AR et al. The efficacy and safety of lyophilized cryoprecipitate in hemophilia A. J Med Assoc Thai 1999;82 (suppl 1):69-73.
14. Brown DC. Adverse events reported in association with the use of monoclonal antibody purified factor VIII c - Monoclate. Semin Hematol 1990;27 (suppl 2):16-7.
15. Lusher JM, Arkin S, Abildgaard CF et al. Kogenate Previously Untreated Patient Study Group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. N Engl J Med 1993;328: 453-9.
16. Zupancic-Salek S, Sertic D et al. Prevalence of inhibitors specific for factor VIII in multitransfused haemophiliacs A. Br J Haematol 1994;87 (suppl 1):191.
17. Sultan Y. French haemophilia Study Group. Prevalence of inhibitors in a population of 3,435 haemophilia patients in France. Thromb Haemost 1992;67:600-2.
18. Gill FM. The natural history of factor VIII inhibitors in patients with haemophilia A. Prog Clin Biol Res 1984;150:19-29.
19. Rieger A, Roisenberg I. Prevalence of factor VIII inhibitors in patients with hemophilia A in Brazil. Thromb Haemost 1999;81:475-6.
20. Kreuz W, Escuriola-Ettingshausen C, Martinez-Saguer I et al. Epidemiology of inhibitors in haemophilia A. Vox Sang 1996;70 (suppl 1): 2-8.
21. Brackmann HH, Schwaab R, Effenberger W et al. Antibodies to factor VIII in hemophilia A patients. Vox Sang 2000;78 (suppl 2):187-90.
22. Colvin BT, Hay CRM, Hill FGH et al. The incidence of factor VIII inhibitors in the United Kingdom, 1990-93. Br J Haematol 1995;89: 908-10.
23. De Biasi R, Rocino A, Papa ML et al. Incidence of factor VIII inhibitor development in hemophilia patients treated with less pure plasma derived concentrates. Thromb Haemost 1994; 71:544-7.
24. Ehrlich HJ, Bray GL, Gomperts ED. Comparison of high responder inhibitor frequency in recent studies of previously untreated patients with hemophilia A. Thromb Haemost 1998;79: 242-3.
25. Schwarzinger I, Pabinger I, Korninger C et al. Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates. Am J Hematol 1987;24: 241-5.
26. Rizza CR, Matthews JM. Effect of frequent factor VIII replacement on the level of factor VIII antibodies in haemophiliacs. Br J Haematol 1982;52:13-24.
27. Nilsson IM. Immune tolerance. Semin Hematol 1994;31:44-8.